Abstract
G Protein-Coupled Receptors (GPCRs) account for 50% of the current drug targets, and remain about
one-third of the drug discovery effort in the drug discovery-development community. As a result of
the sequencing of the human genome, more than 150 orphan and non-chemosensory GPCRs have been
identified for which their cognate ligands or biological functions are unknown. De-orphanization of
those receptors could bring novel therapeutic targets to the industry against which novel
therapeutics could be designed. In addition, current GPCR-based drugs only target ~30% of the
approximately 200 known GPCRs in the genome. This is a rich target class that is highly-druggable.This
Report will benefit those companies, institutions, and individuals requiring an in-depth and
thorough analysis of the technical areas in GPCRs, the emerging technologies in this space, as well
as qualitative and quantitative market analyses, trends, and attendant business opportunities.
Further, this Report provides thorough profiles of those companies currently active within the GPCR
space. | 
View Cart
